- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | Gain Therapeutics ernennt Jeanette Weidner zur Vice President Finance | 2 | Investing.com Deutsch | ||
| 28.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.10. | BTIG reiterates Buy on Gain Therapeutics stock on trial data | 4 | Investing.com | ||
| 01.10. | Gain Therapeutics reports stable motor scores in Parkinson's trial | 1 | Investing.com | ||
| 01.10. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration | 2 | GlobeNewswire (USA) | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.09. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders | 1 | GlobeNewswire (USA) | ||
| 28.09. | Gain Therapeutics: Finanzvorstand tritt zurück, CEO übernimmt interimistisch | 1 | Investing.com Deutsch | ||
| 28.09. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.08. | H.C. Wainwright bestätigt Kaufempfehlung für Gain Therapeutics Aktie | 14 | Investing.com Deutsch | ||
| 31.08. | H.C. Wainwright reiterates Gain Therapeutics stock rating at buy | 1 | Investing.com | ||
| 11.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics GAAP EPS of -$0.11 beats by $0.03 | 5 | Seeking Alpha | ||
| 11.08. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update | 612 | GlobeNewswire (Europe) | BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 16.07. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.07. | Gain Therapeutics plans phase 2 Parkinson's study in Q3 2026 | 1 | Investing.com | ||
| 16.07. | Gain Therapeutics plant Phase-2-Studie zu Parkinson für drittes Quartal 2026 | 1 | Investing.com Deutsch | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update | 448 | GlobeNewswire (Europe) | BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 01.07. | H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval | 3 | Investing.com | ||
| 29.06. | Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease | 692 | GlobeNewswire (Europe) | IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 10,000 | +5,37 % | Novavax: Millionenverkauf - was Anleger jetzt wissen müssen | ||
| INOVIO PHARMACEUTICALS | 1,380 | -4,10 % | ROUNDUP/Aktien New York: Erholung vor nachbörslichen Apple-Zahlen und den Wahlen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben sich am Montag von ihren teils herben Freitagsverlusten erholt. Vor den nachbörslich anstehenden Apple -Geschäftszahlen und den Zwischenwahlen für das... ► Artikel lesen | |
| INFLARX | 1,346 | +2,12 % | InflaRx rutscht ab: Warum die Kidney-Week-Fantasie verpufft | ||
| INTELLIA THERAPEUTICS | 10,980 | +0,18 % | Intellia schließt Rekrutierung für Phase-3-Studie zur ATTRv-PN-Therapie ab | ||
| EDITAS MEDICINE | 2,370 | -2,87 % | Jones Trading initiates Editas Medicine stock coverage with buy rating | ||
| NUREXONE BIOLOGIC | 0,303 | -2,26 % | 2 Seiten der Läsion, p 0,01 und p 0,04: Warum NurExone neben Bewegung auch Myelin misst | ||
| GERON | 0,962 | +0,50 % | GERON CORP - 10-Q, Quarterly Report | ||
| IBIO | 0,733 | +2,52 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 7,840 | -1,51 % | ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ | First patients treated in Germany and Austria, with commercial support from Accord Healthcare
Treatment milestone follows European Commission's February 2026 conditional marketing authorization... ► Artikel lesen | |
| IMMATICS | 6,175 | +0,57 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| MYRIAD GENETICS | 5,900 | +12,34 % | Myriad Genetics Q3 2026 Earnings Call Transcript | ||
| MANNKIND | 3,420 | -1,24 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,450 | +0,77 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| IMMUNIC | 7,172 | +5,97 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in November | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in November
02.11.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 8,160 | +4,88 % | Iovance Biotherapeutics Inc. - IOVA: weißer Rauch bei Lungenkrebs-Daten? | Intraday Trade? Rekordumsatz in Q2 bei Iovance Biotherapeutics. Lifileucel-Therapie mit Mega-Marktpotenzial! Vorbörsliches Gap Up! Iovance Biotherapeutics (IOVA) - US4622601007 Rückblick Nach einer... ► Artikel lesen |
GAIN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.